- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02606526
Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda
A Randomised Controlled Trial in HIV-1 Exposed Ugandan Infants to Estimate Additional Benefits (Non-specific Effects) of BCG
BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis. Though the available literature is mostly from observational study designs, and is fraught with controversy, BCG vaccination at birth, in a high risk population of HIV exposed children, may protect infants against serious infections other than TB. Yet, other studies indicate that giving BCG later in infancy, when the immune system is more mature, may offer even greater protection. The appropriate timing of BCG vaccination could therefore be up for revision. This study will therefore compare BCG vaccination at birth with BCG vaccination at 14 weeks of age in HIV exposed (HE) babies.
Methods: This is an individually randomized clinical trial in 4,500 HIV exposed infants. The intervention is an intra-dermal administration of 0.05 ml of BCG vaccine within 24 hours of birth while the comparator will be an intra-dermal administration of 0.05ml of BCG vaccine at 14 weeks of age.
The main study outcomes include:
- Severe illness in the first 14 weeks of life,
- Innate and adaptive immune responses to mycobacterial, non-mycobacterial antigens and TLR-agonists
- Severe illness in the first 14-52 weeks and 0-52 weeks of life.
The study will be carried in two health centers and one district hospital in Uganda.
Implications: A well-timed BCG vaccination could have important additional benefits in HE infants. This trial could inform the development of programmatically appropriate timing of BCG vaccination for HE infants.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Victoria Nankabirwa, MD, MPH, PhD
- Phone Number: +256755757460
- Email: nankabirwav@gmail.com
Study Contact Backup
- Name: Olive Namugga, MD
- Phone Number: +256790515426
- Email: olivedejackie@yahoo.com
Study Locations
-
-
-
Kampala, Uganda
- Health Centers in Mukono and Kampala districts
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
A baby born at a participating study clinic will be included if s/he:
- has a mother with a positive HIV test (ELISA or rapid test)
- is receiving peri-exposure prophylaxis as part of the standard/national guidelines in Uganda
- has a mother that is of legal age for participation in clinical research studies in Uganda or is an emancipated minor
- has a mother/caregiver that resides within the study area, is not intending to move out of the area in the next 4 months and is likely to be traceable for up to 12 months
- has a mother/caregiver that gives informed consent to random assignment to either of the two trial arms
- has a mother that has received antiretroviral therapy (ART) for at least 4 weeks
Exclusion Criteria:
A new-born child will be excluded if she/he has:
- an identified serious congenital malformation(s)
- severe illness requiring hospitalization
- a birth weight < 2.0 kg
- a mother participating in another clinical trial on the day of enrolment or a mother who will participate in another clinical trial within the next month.
- a mother or other household member with symptoms and signs of tuberculosis on the day of enrolment
- a severely ill mother with (a) condition(s) requiring hospitalization
- a baby with an Apgar score at 5 minutes <7
- a twin or triplet
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm: BCG at birth
Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
|
See previous description
|
Active Comparator: Control arm: BCG at 14 weeks of age
Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
|
See previous description
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Innate and adaptive immune responses against mycobacterial and non-mycobacterial antigens.
Time Frame: 14 weeks post BCG vaccination
|
The following immunological outcomes will be measured in a sub-sample of 180 infants: Innate immune responses (IL-6, TNF, IL-10, IL-1b) against TLR-agonists and adaptive immune responses (IFNy, IL-17, IL-10 and IL-22) against mycobacterial (ESAT-6/CFT10 and PPD) and non-mycobacterial antigens (C.albicans, S. aureus and SARS-CoV-2 spike peptides). |
14 weeks post BCG vaccination
|
Severe illness
Time Frame: The first 14 weeks of life
|
Among children <2 months of age, severe illness (other than TB) will be defined as an acute illness that is associated with any of the following danger signs observed or verified by a clinician: inability to feed or vomiting of everything and unable to keep anything down, lethargy or unconsciousness, severe lower chest in-drawing, axillary temperature of ≥38.0 deg C or <35.5 deg C, grunting, cyanosis, convulsions or a history of convulsions (except epilepsy), and/or requires hospitalization and/or results in death.
Among children ≥2 months of age, severe illness (other than TB) will be defined as an acute illness that is associated with at least one of the following danger signs observed by a clinician: inability to drink or breastfeed lethargy or unconsciousness, vomiting of all feeds, convulsions or a history of convulsions (except epilepsy), and/or requires hospitalization and/or results in death.
Events resulting from violent injury or burns are not considered severe illness.
|
The first 14 weeks of life
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BCG scar at 52 weeks of age
Time Frame: First year of life
|
Presence or absence of a BCG scar at the vaccination site
|
First year of life
|
Severe illness from 48 h after randomization to 14 weeks of life
Time Frame: 48 hours to 14 weeks of life
|
Severe illness as defined for primary outcome 1
|
48 hours to 14 weeks of life
|
Severe illness in weeks 0-52 and 14-52 of life
Time Frame: First 0-52 and 14-52 weeks of life
|
Severe illness as defined for primary outcome 1
|
First 0-52 and 14-52 weeks of life
|
Adverse events
Time Frame: First 52 weeks of life
|
Axillary and cervical lymphadenopathy
|
First 52 weeks of life
|
Infant death
Time Frame: First year of life
|
Death during the first year of life
|
First year of life
|
Growth up to 52 weeks of life
Time Frame: First year of life
|
Growth measured by weight and length
|
First year of life
|
Severe illness until 6 weeks of age
Time Frame: 6 weeks
|
Severe illness as defined for primary outcome 1
|
6 weeks
|
Severe illness until 14 weeks of age within strata of presence or absence of maternal BCG scar
Time Frame: 14 weeks
|
In addition to the above-mentioned outcomes, an analysis plan will be developed which may include any necessary new or modifications in the current secondary outcomes and describe any new secondary analyses, including for sub-group effects".
|
14 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Victoria Nankabirwa, MD, MPH, PhD, School of Public Health, Makerere University
- Principal Investigator: Halvor Sommerfelt, MD, PhD, CISMAC, Center for International Health, University of Bergen
Publications and helpful links
General Publications
- Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskar T, Sommerfelt H; PROMISE- EBF Study Group. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. BMC Public Health. 2015 Feb 22;15:175. doi: 10.1186/s12889-015-1497-8.
- Nankabirwa V, Tumwine JK, Namugga O, Tylleskar T, Ndeezi G, Robberstad B, Netea MG, Sommerfelt H. Early versus late BCG vaccination in HIV-1-exposed infants in Uganda: study protocol for a randomized controlled trial. Trials. 2017 Mar 31;18(1):152. doi: 10.1186/s13063-017-1881-z.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-114
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diarrhoea
-
Wageningen UniversityCompleted
-
PfizerDanisco/DupontWithdrawn
-
National Health Service, United KingdomFerring Pharmaceuticals; Hull University Teaching Hospitals NHS Trust; North... and other collaboratorsCompleted
-
IpsenCompleted
-
IpsenCompleted
-
International Centre for Diarrhoeal Disease Research...Bill and Melinda Gates FoundationCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
InQpharm GroupCompleted
-
University of MalayaUnknown
-
Dr. Philipp Zanger, MD MSc DTMCompleted
Clinical Trials on BCG at birth
-
Sharp HealthCareUniversity of Alabama at Birmingham; University of Pittsburgh; University of... and other collaboratorsRecruitingNeurodevelopmental AbnormalityUnited States, Ireland, Canada, Germany
-
Policlinico Abano TermeActive, not recruitingAcidosis | Hematocrit AnemiaItaly
-
Bandim Health ProjectUniversity of Southern DenmarkRecruitingInfant Mortality | BCGGuinea-Bissau
-
Marmara UniversityNot yet recruitingBreastfeeding | Breastfeeding Support
-
Bandim Health ProjectUniversity of Southern DenmarkRecruitingMorbidity;Newborn | Non-specific Effects of Vaccines | Death, Infant | Morbidity;Infant | Death; NeonatalGuinea-Bissau
-
Centre Hospitalier Universitaire de Saint EtienneTerminated
-
Bandim Health ProjectOdense University Hospital; Odense Patient Data Explorative Network; Municipality...CompletedCovid19 | Immunosenescence | Vaccine Preventable Disease | Morbidity | Non-specific Effects of Vaccines | Heterologous ImmunityDenmark
-
Amasya UniversityAtaturk UniversityNot yet recruitingSatisfaction, Patient | Pain, Labor
-
Dartmouth-Hitchcock Medical CenterTerminated